tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BIIB Stock Latest News

Biogen’s New Study on Felzartamab: A Potential Game-Changer for IgAN Treatment
Company AnnouncementsBiogen’s New Study on Felzartamab: A Potential Game-Changer for IgAN Treatment
20h ago
BIIB
Biogen’s Innovative Approach to SMA Treatment: The PIERRE-PK Study
PremiumCompany Announcements
Biogen’s Innovative Approach to SMA Treatment: The PIERRE-PK Study
2d ago
BIIB
Biogen’s New Study on MS Drug Vumerity: Key Insights for Investors
PremiumCompany Announcements
Biogen’s New Study on MS Drug Vumerity: Key Insights for Investors
2d ago
BIIB
Biogen’s Promising Phase 3 Trial: Felzartamab for Kidney Transplant Rejection
PremiumCompany Announcements
Biogen’s Promising Phase 3 Trial: Felzartamab for Kidney Transplant Rejection
2d ago
BIIB
Biogen’s Spinraza Study: Real-World Insights and Market Impact
PremiumCompany Announcements
Biogen’s Spinraza Study: Real-World Insights and Market Impact
2d ago
BIIB
Avidity, Phathom mentioned as potential takeout targets at Needham
PremiumThe FlyAvidity, Phathom mentioned as potential takeout targets at Needham
2d ago
BMY
NVO
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: Market Implications
Premium
Company Announcements
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: Market Implications
3d ago
BIIB
Biogen’s New Study on Omaveloxolone for Young FA Patients: Market Insights
Premium
Company Announcements
Biogen’s New Study on Omaveloxolone for Young FA Patients: Market Insights
5d ago
BIIB
Biogen’s SMA Study in China: A Strategic Move in the Healthcare Market
PremiumCompany Announcements
Biogen’s SMA Study in China: A Strategic Move in the Healthcare Market
8d ago
BIIB
Biogen’s Hold Rating: Navigating Current Challenges and Future Opportunities
PremiumRatings
Biogen’s Hold Rating: Navigating Current Challenges and Future Opportunities
8d ago
BIIB
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: A Market Game-Changer?
PremiumCompany Announcements
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: A Market Game-Changer?
9d ago
BIIB
Stoke Therapeutics, Biogen present data from EMPEROR study
PremiumThe Fly
Stoke Therapeutics, Biogen present data from EMPEROR study
9d ago
BIIB
STOK
Biogen, Stoke Therapeutics present data from studies of zorevunersen
PremiumThe FlyBiogen, Stoke Therapeutics present data from studies of zorevunersen
9d ago
BIIB
STOK
Closing Bell Movers: Merit Medical Systems gains after Q2 outlook
Premium
The Fly
Closing Bell Movers: Merit Medical Systems gains after Q2 outlook
12d ago
BIIB
MMSI
Biogen sees Q2 EPS impacted by 26c R&D expense charge
Premium
The Fly
Biogen sees Q2 EPS impacted by 26c R&D expense charge
12d ago
BIIB
Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy
PremiumCompany Announcements
Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy
15d ago
BIIB
Biogen’s Litifilimab Study: A Long-Term Look at SLE Treatment
PremiumCompany Announcements
Biogen’s Litifilimab Study: A Long-Term Look at SLE Treatment
16d ago
BIIB
Biogen’s Promising Phase 3 Trial: Felzartamab for Kidney Transplant Rejection
PremiumCompany Announcements
Biogen’s Promising Phase 3 Trial: Felzartamab for Kidney Transplant Rejection
16d ago
BIIB
Biogen’s Pivotal Study on ThecaFlex DRx™ System for SMA: A Market Game-Changer?
PremiumCompany Announcements
Biogen’s Pivotal Study on ThecaFlex DRx™ System for SMA: A Market Game-Changer?
16d ago
BIIB
Biogen’s Lecanemab Study: A Potential Game-Changer in Alzheimer’s Treatment?
PremiumCompany AnnouncementsBiogen’s Lecanemab Study: A Potential Game-Changer in Alzheimer’s Treatment?
16d ago
BIIB
Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy
Premium
Company Announcements
Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy
17d ago
BIIB
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment?
Premium
Company Announcements
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment?
18d ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >